That's Interesting

That's interesting archive

That's Interesting

Māori leadership is standing out strongly in students emerging in the healthcare sector who are united in one goal, improving Māori healthcare outcomes.

Group Chief Executive Josephine Gagan from New Zealand Health Group said they were very impressed by the high calibre of the 172 applications they received for their Māori Health Leadership Scholarship programme. The $20,000 scholarship awarded annually is one of New Zealand Health Group’s initiatives in building equity in health and wellness in Aotearoa New Zealand, and enables more Māori to be in decision-making leadership roles within the health sector. 

Click the link above to read the full press release.

Pharmac’s chief medical officer Dr David Hughes has today announced the decision to fund a biosimilar adalimumab (Amgevita), improving access to adalimumab for more than 700 New Zealanders.

Adalimumab is used to treat a range of rheumatology, gastrointestinal, dermatological, and other autoimmune conditions. Around 6,400 kiwis have this injection, often fortnightly.

You can read the full Pharmac media release, and find helpful resources on this page.

A simple ‘nudge’ letter to GPs pointing out their antibiotic prescribing was “out of whack” with their local peers led to a sizeable drop in overprescribing, a NZMA study published in Ocotber finds. Fiona Cassie of New Zealand Doctor Rata Aotearoa reports. 

What was new about the intervention programme was the direct feeding back to individual GPs on how their individual prescribing compared with their peers.

From cultural sensitivity to cultural safety via cultural competency, it has been a decades-long journey for health professionals. New Zealand Doctor Rata Aotearoa editor Barbara Fountain reports from GP21: Conference for General Practice in Wellington in August.

Changing the language of diabetes can make a powerful and positive difference to the emotional well-being, self-care and health outcomes of people affected by diabetes. It also affects community and government support for funding diabetes care, prevention and research.

Diabetes Australia encourages everyone communicating about diabetes, or about people affected by diabetes, to choose and use their words carefully to support all people affected by diabetes. This position statement is intended as a guide for people working in healthcare, the media, government and policy, academia, industry, as well as employers and the community.

Empagliflozin (with and without metformin) has been funded since 1 February 2021 and dulaglutide has been funded since 1 September 2021. Both medicines are available to people with high-risk type 2 diabetes who meet special authority criteria. 

This is the first time Pharmac has specifically named Māori and Pacific ethnicities within the funding criteria, to proactively promote equity of access to these medicines. 

Pharmac is actively monitoring and reporting on the number of people who are being started on empagliflozin and dulaglutide under the special authority criteria and providing monthly updates. See the latest uptake figures here.

Recent report from the Health Quality & Safety Commission of New Zealand.

Bula Sautu uses national data to show the complex contributing factors that impact on health for Pacific peoples, from maternity to end of life, using a life-course approach. The report brings together a diverse range of Pacific health and equity experts to share their views of how effectively (or ineffectively) the health system is performing for Pacific peoples.

Addressing improvement in Pacific health is challenging, but there is a way forward. This way forward involves strong and supported Pacific leadership, effective partnerships with Pacific communities, and systematic, coordinated action within all levels of the health and social sectors and beyond. Within the health sector, there are a number of key actions that organisations and individual services can take, many of them within existing resources. These actions are presented as a seven-step framework to improve Pacific health. 

The Health Quality & Safety Commission of New Zealand has developed a Te Ao Māori Framework in partnership with Māori health providers, Whānau Ora providers and participating district health boards across Aotearoa New Zealand. Read more about the framework and download PDFs from the HQSC website.

PODCAST: Dr Rinki Murphy discusses type 2 diabetes management with a focus on GLP-1 receptor agonists, including how to use dulaglutide now that it has Medsafe approval. This Goodfellow Unit podcast also contains links to other useful resources.

Written by Dr Vicki Mount with expert review by Dr Ryan Paul, this Goodfellow Unit MedCase considers the place of dulaglutide (Trulicity) alongside other therapies for T2D management.